在本次大会上,一项题为“Validation of the 2022 European Leukemianet Risk Stratification of Acute Myeloid Leukemia(2022年欧洲白血病网(ELN)急性髓系白血病(AML)风险分层的验证)”的研究入选壁报展示(P4310),为AML风险分层带来重要启示。...
在本次大会上,一项题为“Validation of the 2022 European Leukemianet Risk Stratification of Acute Myeloid Leukemia(2022年欧洲白血病网(ELN)急性髓系白血病(AML)风险分层的验证)”的研究入选壁报展示(P4310),为AML风险分层带来重要启示。本期特整理如下,供大家提前阅览。 研究简介 背景 AML在临床结局和疾病生物学...
在本次大会上,一项题为“Validation of the 2022 European Leukemianet Risk Stratification of Acute Myeloid Leukemia(2022年欧洲白血病网(ELN)急性髓系白血病(AML)风险分层的验证)”的研究入选壁报展示(P4310),为AML风险分层带来重要启示。本期特整理如下,供大家提前阅览。 编者按:第66届美国血液学会(ASH)年会将于...
Min-Yen Lo,et al. Validation of the prognostic significance of the 2022 European LeukemiaNet risk stratification system in intensive chemotherapy treated aged 18 to 65 years patients with de novo acute myeloid leukemia.Am J He...
Models excluding results for ASXL1, CEBPA, RUNX1 and TP53, demonstrated that these mutations provide a limited overall contribution to risk stratification across the entire population, given the low frequency of mutations and confounding risk factors. Conclusions: While European LeukemiaNet guidelines ...
We performed a post hoc analysis of the GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) AML1310 trial to investigate the applicability of the ELN2017 risk stratification to our study population. In this trial, after induction and consolidation, patients in complete remission were to ...
R code for replicating results in Archer et al., "Improving risk stratification for 2022 European LeukemiaNet favorable-risk patients with acute myeloid leukemia" hdcuremodels The hdcuremodels R package was used for fitting high-dimensional mixture cure models. A vignette to illustrate usage is inc...
Thus, ASXL1 mutations identify a previously unrecognized high-risk subgroup among older CN-AML patients who would be categorized as low-risk based on currently used classification systems. ELN Favorable/ASXL1-mut patients might therefore be considered candidates for experimental treatment approaches. ...
The European LeukemiaNet (ELN) risk stratification system is commonly applied in AML but the clinical significance is unknown in s/tAML. We analyzed 644 s/tAML or de novo AML patients receiving HSCT. s/tAML associated with older age and adverse risk, including higher ELN risk. Overall, s/...
Prognostic analysis according to the 2017 ELN risk stratification by genetics in adult acute myeloid leukemia patients treated in the Japan Adult Leukemia Study Group (JALSG) AML201 studyingentaconnectLeukemia Research Oxford